Nicole Murphy Biogen Inc. (BIIB) insider trading activity

BIIB Quotes by TradingView

Nicole Murphy is Head of Pharm Ops and Tech of BIOGEN INC.. Currently has a direct ownership of 9,634 shares of BIIB, which is worth approximately $1.67 Million. The most recent transaction as insider was on Apr 01, 2024, when has been sold 117 shares (Common Stock) at a price of $214.83 per share, resulting in proceeds of $25,135. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 9.63K
0% 3M change
68.96% 12M change
Total Value Held $1.67 Million

Nicole Murphy Transaction History

Date Transaction Value Shares Traded Shares Held Form
Apr 01 2024
SELL
Payment of exercise price or tax liability
$25,135 $214.83 p/Share
117 Reduced 1.2%
9,634 Common Stock
Apr 01 2024
BUY
Exercise of conversion of derivative security
-
240 Added 2.4%
9,751 Common Stock
Feb 16 2024
SELL
Payment of exercise price or tax liability
$133,638 $219.08 p/Share
610 Reduced 6.08%
9,417 Common Stock
Feb 16 2024
BUY
Exercise of conversion of derivative security
-
1,260 Added 11.59%
9,613 Common Stock
Feb 09 2024
SELL
Payment of exercise price or tax liability
$183,385 $240.98 p/Share
761 Reduced 7.99%
8,767 Common Stock
Feb 09 2024
BUY
Exercise of conversion of derivative security
-
2,272 Added 19.25%
9,528 Common Stock
Feb 08 2024
SELL
Payment of exercise price or tax liability
$153,311 $240.3 p/Share
638 Reduced 8.08%
7,256 Common Stock
Feb 08 2024
BUY
Exercise of conversion of derivative security
-
2,101 Added 21.02%
7,894 Common Stock
Mar 31 2023
SELL
Payment of exercise price or tax liability
$32,251 $278.03 p/Share
116 Reduced 1.99%
5,702 Common Stock
Mar 31 2023
BUY
Exercise of conversion of derivative security
-
239 Added 3.95%
5,818 Common Stock
Feb 17 2023
SELL
Payment of exercise price or tax liability
$64,862 $278.38 p/Share
233 Reduced 4.37%
5,099 Common Stock
Feb 17 2023
BUY
Exercise of conversion of derivative security
-
480 Added 7.92%
5,579 Common Stock
Feb 10 2023
SELL
Payment of exercise price or tax liability
$397,098 $286.3 p/Share
1,387 Reduced 20.64%
5,332 Common Stock
Feb 10 2023
BUY
Exercise of conversion of derivative security
-
2,611 Added 30.2%
6,034 Common Stock
Jan 25 2023
BUY
Grant, award, or other acquisition
-
1,340 Added 24.6%
4,108 Common Stock
Dec 02 2022
SELL
Payment of exercise price or tax liability
$11,657 $298.9 p/Share
39 Reduced 1.39%
2,768 Common Stock
Dec 02 2022
BUY
Exercise of conversion of derivative security
-
131 Added 4.46%
2,807 Common Stock
Aug 01 2022
SELL
Payment of exercise price or tax liability
$66,754 $209.26 p/Share
319 Reduced 10.65%
2,676 Common Stock
Aug 01 2022
BUY
Exercise of conversion of derivative security
-
1,080 Added 27.01%
2,919 Common Stock
Apr 01 2022
SELL
Payment of exercise price or tax liability
$17,695 $210.65 p/Share
84 Reduced 4.43%
1,812 Common Stock
Apr 01 2022
BUY
Exercise of conversion of derivative security
-
239 Added 11.19%
1,896 Common Stock
Feb 18 2022
SELL
Payment of exercise price or tax liability
$23,077 $209.79 p/Share
110 Reduced 6.23%
1,657 Common Stock
Feb 18 2022
BUY
Exercise of conversion of derivative security
-
371 Added 17.35%
1,767 Common Stock
Feb 12 2022
SELL
Payment of exercise price or tax liability
$19,742 $214.59 p/Share
92 Reduced 6.18%
1,396 Common Stock
Feb 12 2022
BUY
Exercise of conversion of derivative security
-
263 Added 15.02%
1,488 Common Stock
NM

Nicole Murphy

Head of Pharm Ops and Tech
Cambridge, MA

Track Institutional and Insider Activities on BIIB

Follow BIOGEN INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BIIB shares.

Notify only if

Insider Trading

Get notified when an Biogen Inc. insider buys or sells BIIB shares.

Notify only if

News

Receive news related to BIOGEN INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on BIIB